Mediworld Middle East

#AfriSummit2024, hosted by PRA Consultancy and organized by Hubplus Events in collaboration with Pioneers , is set to take place from November 3-6, 2024, at the Grand Nile Tower in #Cairo, #Egypt. This #pivotal event will unite key stakeholders from the #pharmaceutical and #medicaldevice sectors, regulatory bodies, and solution providers from across #Africa and beyond, with the goal of enhancing regulatory harmonization and improving access to safe, effective, and high-quality medicines. Dr. Najiba Al Shezawy, co-founder of AfriSummit, emphasizes the importance of this summit: "Regulatory harmonization ensures all Africans have access to safe and effective medicines. AfriSummit is key in making significant strides in this area." The summit will feature a lineup of expert speakers from national regulatory bodies, the pharmaceutical and medical device industries, and global health organizations. Key topics include regulatory convergence, compliance, and innovative pathways. Attendees can also participate in specialized workshops on Pharmacovigilance and eCTD, gaining insights into the latest advancements and best practices. A highlight of AfriSummit 2024 will be a presentation on the current state of the African Medicines Agency Treaty Alliance (AMATA) by AUDA-NEPAD, followed by a series of valuable sessions and panel discussions. Topics will cover reliance in post-approval changes, MDSAP audits, GMP site inspections for medical devices, and combating counterfeits in the medical device supply chain. In support of this critical initiative, Haleon will serve as the Titanium Sponsor, with Abbott and VISIOTT Traceable Packaging Solutions | TPS as Gold Sponsors, VECTOR Life Sciences Ltd. (Pty) as Silver Sponsor, and Uniclue for Consultation Services as Associate Sponsor. The Regulatory Affairs Professionals Society (RAPS) will be the Networking Partner, EVOTEQ will sponsor lunch, and EXTEDO will support the eCTD AfriSummit Workshop. Dr. Mona Al Moussli, co-founder of AfriSummit, expresses her enthusiasm: "The 4th edition of AfriSummit in Cairo epitomizes progress and innovation, highlighting the importance of harmonization and reliance in Africa. This year’s summit will be a catalyst for positive change in the pharmaceutical regulatory landscape across the continent." #AfriSummit2024 #PharmaceuticalRegulation #RegulatoryHarmonization #HealthcareInnovation #MedicalDevices #Pharmacovigilance #eCTD #AMA #AfricanPharma #GlobalHealth #dubai #Uae #africa #pharma #summit

Zepp Health Corporation, a leader in smart wearables, and Wild.AI, a cutting-edge #wellness app for #women, have announced a groundbreaking integration that brings Wild.AI’s advanced health and wellness solutions directly to Amazfit smartwatches, starting with the Amazfit Active series. This collaboration marks the first time Wild.AI’s specialized app will be available directly on a smartwatch, focusing on female physiology and training needs. The integration will soon extend to other Amazfit series, offering advanced health management solutions tailored specifically for women at no additional cost. Users will benefit from personalized readiness scores, insights, recommendations, and training plans based on extensive research, including over 450 whitepapers. The app provides exercise and diet recommendations aligned with menstrual and hormonal cycles, supporting women through all life stages, from reproductive years to perimenopause and beyond. Helene Guillaume Pabis, Founder and CEO of Wild.AI, shared her enthusiasm: "Our app aggregates data from wearables and manual inputs to provide a female readiness score, guiding personalized training, nutrition, and recovery plans. At Wild.AI, we’re committed to empowering women with health technologies that embrace female physiology. This collaboration with Zepp Health is a significant step in making tailored health solutions accessible outside the Wild.AI app." Wayne Huang CEO of Zepp Health, emphasized the impact of this integration: “At Zepp Health, we are dedicated to advancing our smartwatch technology to meet the unique health needs of women. This integration with Wild.AI is a testament to our commitment to providing cutting-edge health insights and tools that empower women to take control of their wellness.” With this integration, Amazfit smartwatches will now offer real-time, personalized health insights and the convenience of managing fitness and wellness directly from the wrist. This move is set to revolutionize how women engage with their health and fitness, making Amazfit a pioneer in female-tailored smartwatch technology. #ZeppHealth #WildAI #WomenHealth #SmartwatchIntegration #Amazfit #Fitness #Wellness #HealthTech #Innovation #womenhealth #women #exercise #dubai #uae

NanoSyrinx is pleased to announce the successful closure of a £10 million ($13 million) financing round. This significant milestone will accelerate the development of their innovative nanosyringe platform, designed to deliver biologic therapeutics directly to previously 'undruggable' intracellular targets. The funding round was co-led by BGF, Octopus Ventures, and M Ventures , with notable contributions from existing investors IQ Capital and Meltwind Advisory LLP, and global medicines company Eli Lilly and Company. In addition to the funding, NanoSyrinx is excited to welcome Dr. Edwin Moses as the new Chairman of the Board of Directors. Dr. Moses, a distinguished leader in the life sciences sector, brings over 30 years of experience and a proven track record in scaling biotech companies and leading successful exits. Dr. Joe Healey CEO of NanoSyrinx, expressed his enthusiasm: “Edwin Moses has extensive experience as a CEO and Chairman, with a strong background in biotech fundraising, strategic partnerships, and successful exits. His appointment as Chair of the Board comes at a crucial time alongside this financing, positioning NanoSyrinx to further develop its intracellular drug delivery technology.” Dr. Moses shared his excitement about the role: “NanoSyrinx’s technology offers a tremendous opportunity to address the challenging problem of intracellular delivery of therapeutics. I am thrilled to join the Board and build on the momentum from this latest fundraise, supporting the company in advancing this unique platform, which has the potential to create significant value and improve patients' lives.” Lucy Edwardes Jones, Investor at BGF, added: “While there have been substantial advances in biologic therapies, the challenge of delivery remains a key issue. The potential of NanoSyrinx’s technology to overcome this challenge is exciting, as it can enable new drugs to reach previously inaccessible disease targets.” NanoSyrinx looks forward to making significant strides in intracellular medicine and bringing groundbreaking therapies to those in need. #NanoSyrinx #Biotech #Investment #Leadership #HealthcareInnovation #IntracellularDelivery #DrugDevelopment #dubai #uae #medical #innovation #tech #like #share #subscribe

Belite Bio, is pleased to announce the appointment of Dr. Hendrik P. N. Scholl as Chief Medical Officer. A globally recognized authority on Stargardt disease and age-related macular degeneration (AMD), Dr. Scholl brings decades of expertise in treating retinal diseases. His extensive experience, including leadership roles in the ophthalmology field and involvement in Belite’s clinical trials, will be invaluable as the company advances its lead candidate, Tinlarebant, through Phase 3 studies. Dr. Scholl shared, “I’m excited to join Belite Bio at this pivotal time, and I look forward to contributing to the development of transformative therapies for Stargardt disease and dry AMD.” #BeliteBio #Leadership #RetinalDiseases #Ophthalmology #dubai #uae #StargardtDisease #AMD #DrugDevelopment #ClinicalResearch #Biopharmaceuticals #Innovation #MedicalAdvancements #Healthcare #PharmaceuticalIndustry #medical #tech #digital

ZEISS Medical Technology is set to unveil its latest innovations in #3D #visualization and #digital tools at the European Society of Retina Specialists (EURETINA) conference. ZEISS will highlight advanced technologies, including the #ZEISSARTEVO® 850 3D digital ophthalmic microscope, which offers surgeons enhanced depth of field and true color imaging for precise procedures. Attendees will also experience the integration of DORC’s EVA NEXUS surgical system, now part of the #ZEISS #Retina #Workflow, enhancing efficiency and responsiveness during surgery. Dr. Euan S. Thomson, President of the Ophthalmology Strategic Business Unit at ZEISS, shared, “We’re excited to showcase our expanding ZEISS Retina Workflow, designed to help retinal surgeons deliver efficient diagnoses and treatment plans, improving patient outcomes.” ZEISS will also feature #AIpowered tools like CIRRUS® PathFinder™, revolutionizing retinal diagnostics by streamlining the review of OCT data and enabling #personalized #patientcare. Join ZEISS at EURETINA 2024 to explore these groundbreaking innovations in #ophthalmic #surgery. #ZEISS #EURETINA2024 #3DVisualization #OphthalmicSurgery #DigitalHealth #RetinaWorkflow #SurgicalInnovation #AIInHealthcare #MedicalTechnology #Ophthalmology #Retina #dubai #uae

Varian, a Siemens Healthineers company, has launched its HyperSight™ imaging solution for TrueBeam and Edge systems across the #AsiaPacific region (excluding China). This cutting-edge #technology enhances image quality and streamlines #workflows, empowering #clinicians to deliver more precise and efficient #radiation therapy. "HyperSight has been instrumental in improving our workflow and boosting our confidence in imaging and treatment," said Dr. Sujith Baliga of The Ohio State University Wexner Medical Center. "We can now reduce inefficiencies and focus on enhancing patient comfort and delivering optimal care." Varian APJ President, Hideaki Mori, added, "Guided by evolving clinical needs, HyperSight exemplifies our commitment to advancing clinical practice and providing high-quality solutions for cancer patients." #Radiotherapy #CancerTreatment #Medical #Imaging #HealthcareInnovation #PrecisionMedicine #PatientCare #dubai #uae

King Faisal Specialist Hospital and Research Center (KFSHRC) reaffirms its dedication to fostering inclusivity and diversity in medical education, positioning itself as a leader in modern healthcare. With professionals from over 77 nationalities, KFSHRC's commitment to collaboration and knowledge-sharing drives innovation and excellence. In 2023, KFSHRC demonstrated its global reach by participating in the AMEE - The International Association for Health Professions Education in Glasgow. This, along with their international certification programs and cultural exchange initiatives, ensures that healthcare professionals are equipped for a globalized medical environment. #HealthcareLeadership #DiversityAndInclusion #MedicalEducation #GlobalHealthcare #InnovationInHealthcare #dubai #uae #medical #news #updates

SOPHiA GENETICS, a global leader in data-driven medicine, has reached a new milestone in its partnership with AstraZeneca by accelerating the global rollout of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™. “Our collaboration with AstraZeneca has the potential to dramatically accelerate global access to liquid biopsy testing, especially in underserved populations,” said Philippe Menu, M.D., Ph.D., Chief Medical and Chief Product Officer, SOPHiA GENETICS. Kristina Rodnikova, Head of Global Oncology Diagnostics at AstraZeneca, added, “We are confident this rollout will further support access to testing and aid in providing data-driven treatment options to patients around the world.” The partnership aims to reshape cancer diagnostics and treatment while advancing research through real-world data. #CancerResearch #LiquidBiopsy #DataDrivenMedicine #HealthcareInnovation #Oncology #GlobalHealth #Diagnostics #CancerTreatment #SOPHiAGenetics #AstraZeneca #dubai #uae #AI

In a significant step towards enhancing #healthcare access in the #UAE, M42 Health has announced a strategic investment partnership with the UAE’s Ministry of Defence to manage and operate Zayed Military Hospital in Al Batayeh, Sharjah. This collaboration will provide over three million people across the northern UAE with access to world-class #medical care, including specialized services for military personnel and their families. Hasan Jasem Al Nowais, Managing Director and Group CEO of M42, shared, "Together with the Ministry of Defence, we are bringing advanced services and specialized expertise closer to the people in the northern regions, ensuring the highest quality of care for all." Dr. Aysha Aldhaheri, the executive director of the Military Health Executive Directorate in the UAE Ministry of Defence, said: “We are pleased with the first-of-its-kind military-civilian partnership between the Ministry of Defence and M42 to deliver world-class medical services to our servicemen and women and their families, and the wider population of the northern regions of the UAE. This collaboration clearly reflects our unwavering commitment to providing the highest standards of healthcare in the Armed Forces, while at the same time strengthening our role in the national health ecosystem to improve access to specialized medical care for a larger segment of society.” This partnership not only strengthens M42’s healthcare network but also reflects its commitment to transforming healthcare delivery and integrating the UAE's healthcare ecosystem. M42 will continue to deliver cutting-edge healthcare through facilities like Imperial College London Diabetes Centre, Cleveland Clinic Abu Dhabi, and Healthpoint, further redefining medical care standards in the region. #Healthcare #Innovation #MilitaryHealthcare #UAEHealthcare #M42Expansion #WorldClassHealthcare #StrategicPartnership #PatientCare #NorthernUAE #dubai #Uae #healthcare #medtech #technology #medical

RFiD Discovery has announced the launch of its innovative Patient Discharge Management system, aimed at transforming how hospitals manage bed availability. The system leverages advanced #RFID technology to offer a faster and more accurate solution, enhancing patient care and operational efficiency. Simon Dawkins, Lead RFID Consultant – Healthcare at RFiD Discovery, commented, "In today’s fast-paced healthcare environment, timely and accurate bed management is essential. Our Patient Discharge Management system provides hospitals with a seamless solution that not only speeds up the discharge process but also frees up valuable time for healthcare staff to focus on what matters most — patient care." The system integrates RFID-enabled wristbands and a Smart Drop Reader, allowing real-time updates of bed availability with minimal disruption to existing processes. RFiD Discovery says this innovation will streamline discharge processes, improve bed turnaround times, and ultimately contribute to better patient outcomes. #dubai #uae #Healthcare #Innovation #PatientCare #RFIDTechnology #HospitalManagement #OperationalEfficiency #Healthcare #Transformation #digital #medical #medtech RFiD Discovery | A Paragon ID company #new #news #tech